Table 3: Level 2 Checklist for Screening Full-Text Articles and Clinical Effectiveness Study Reports

Reviewer: _____ **Date:** _____			
Ref ID: **Author:** **Publication Year:**			
Did the study include:		**Yes (Include)**	**No (Exclude)**
A.	**The population of interest:**		
	Adults (mean age of 18 years or older) with any of the following types of histologically confirmed relapsed or refractory large B-cell lymphoma:[a] • DLBCL, primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma	☐	☐
	Mixed population, including adults with eligible types of relapsed or refractory large B-cell lymphoma, and results are reported separately for the eligible population	☐	☐
	Mixed population, including adults with eligible types of relapsed or refractory large B-cell lymphoma, but results are not reported separately. • There are sufficient numbers of eligible patients (66% or more) to include in the study, but results will be reported and discussed separately.		
B.	**The intervention of interest:**		
	• Axicabtagene ciloleucel[b]	☐	☐
C.	**A comparator of interest:**		
	• Other CAR T-cell therapies (e.g., tisagenlecleucel)	☐	☐
	• Salvage chemotherapy	☐	☐
	• No comparator	☐	☐
	• No additional therapy		
D.	**Outcome(s) of interest:**		
•	Clinical effectiveness outcomes (e.g., response rate, survival, persistence of CAR T cells, health-related quality of life, patient-reported outcomes, and the need for subsequent treatment)	☐	☐
•	Safety/harms outcomes (e.g., mortality, AEs, CRS, febrile neutropenia, B-cell aplasia, neurological effects including hallucination and dysphasia, infections, development of secondary malignancy, hospitalization)	☐	☐
•	Other outcomes (frequency of manufacturing failure, management of AEs)	☐	☐
E.	**A study design of interest:**		
	• RCTs	☐	☐
	• Non-randomized controlled trials • Single-arm studies	☐	☐
	• Cohort studies	☐	☐
	• Case-control studies	☐	☐
	• Case series	☐	☐
	• Indirect treatment comparisons, network meta-analyses	☐	☐
F.	**Notes:**		
G.	**Selected for inclusion in the review** [c]	**Yes** ☐	**No** ☐
H.	**Reason for exclusion**	☐ Irrelevant population ☐ Irrelevant intervention	

Reviewer: _____ Date: _____		
Ref ID: **Author:** **Publication Year:**		
Did the study include:	**Yes (Include)**	**No (Exclude)**
	☐ Irrelevant comparator ☐ Irrelevant outcomes ☐ Irrelevant study design ☐ Other (specify):	

AE= adverse event; CAR = chimeric antigen receptor; CRS = cytokine release syndrome; DLBCL = diffuse large B-cell lymphoma; RCT = randomized controlled trial.

[a] Eligible indications include patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

[b] Prescribing information indicates that the dose of axicabtagene ciloleucel is 2×10^6 CAR-positive viable T cells per kg body weight, with a maximum of 2×10^8 CAR-positive viable T cells in approximately 68 mL.[15] Studies in which axicabtagene ciloleucel was administered at a different dose will also be eligible for inclusion, but the evidence will be considered separately.

[c] Both reviewers must answer "yes" to all questions for inclusion at the full-text level. If there is a discrepancy between the reviewers, disagreements will be resolved by discussion or with the involvement of a third reviewer, if necessary.